Search results for "blind"

showing 3 items of 1063 documents

MR Imaging of Uterus Didelphys Transverse Vaginal Septum Causing Hematometrocolpos and Renal Agenesis

2002

The association of uterus didelphys and unilateral blind vagina with ipsilateral renal agenesis is an infrequent urogenital malformation distinguished by a lesion of the mesonephric duct. In most patients, symptoms are present at the beginning of the menstrual cycle because a transverse vaginal septum on one side obstructs the flow of menses, which consequently collect. Magnetic resonance imaging allows a precise delineation of this congenital abnormality, clearly demonstrating the transverse vaginal septum with hematometrocolpos and uterus didelphys. Extending the magnetic resonance study to the abdomen and employing coronal sections with a wide field of view is important to search for ass…

urogenital systemGenitourinary systembusiness.industrymedia_common.quotation_subjectObstetrics and GynecologyAnatomyBlind vaginamedicine.diseaseMr imagingUterus didelphysMesonephric ductLesionmedicineRadiology Nuclear Medicine and imagingUterus malformation MR imagingmedicine.symptombusinessRenal agenesisMenstrual cyclemedia_commonJournal of Women's Imaging
researchProduct

Explicit behavioral detection of visual changes develops without their implicit neurophysiological detectability

2011

Change blindness is a failure of reporting major changes across consecutive images if separated, e.g., by a brief blank interval. Successful change detection across interrupts requires focal attention to the changes. However, findings of implicit detection of visual changes during change blindness have raised the question of whether the implicit mode is necessary for development of the explicit mode. To this end, we recorded the visual mismatch negativity (vMMN) of the event-related potentials (ERPs) of the brain, an index of implicit pre-attentive visual change detection, in adult humans performing an oddball-variant of change blindness flicker task. Images of 500 ms in duration were prese…

visual mismatch negativitygenetic structuresflicker paradigmMismatch negativityStimulus (physiology)Electroencephalographyevent-related potentialsBlanklcsh:RC321-571Developmental psychologyBehavioral NeuroscienceEvent-related potentialInter-stimulus intervalmedicineOriginal Research Articleskin and connective tissue diseaseslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOddball paradigmta515Biological Psychiatrychange blindnessmedicine.diagnostic_testPsychiatry and Mental healthNeuropsychology and Physiological PsychologyNeurologyChange blindnesssense organsPsychologyChange detectionNeuroscienceoddball paradigmCognitive psychologyFrontiers in Human Neuroscience
researchProduct

Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 mon…

2014

Summary Background In patients with COPD, exacerbations are associated with poor quality of life and may shorten survival. Prevention of exacerbations is, therefore, a key objective in COPD management. Indacaterol, a once-daily ultra-long-acting β 2 -agonist, has been shown to reduce exacerbations in various studies. This pooled analysis evaluated the effect of indacaterol on exacerbations versus placebo. Methods Six-month data were pooled from three randomized, double-blind, and placebo-controlled studies: indacaterol 300 μg versus placebo (1 year); indacaterol 150 μg and 300 μg versus placebo (6 months); and indacaterol 150 μg versus placebo (6 months). All treatments were administered on…

β2-agonistPulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationKaplan-Meier EstimateQuinolonesPlaceboDrug Administration SchedulePooled analysisExacerbationsPulmonary Disease Chronic ObstructiveFEV1/FVC ratioDouble-Blind MethodForced Expiratory VolumeInternal medicineHumansCOPDMedicineAdrenergic beta-2 Receptor AgonistsRandomized Controlled Trials as TopicIndacaterolCOPDDose-Response Relationship Drugbusiness.industryMinimal clinically important differenceHazard ratiomedicine.diseaseConfidence intervalBronchodilator AgentsClinical Trials Phase III as TopicAnesthesiaIndansIndacaterolbusinessBronchodilatormedicine.drugRespiratory Medicine
researchProduct